利特昔替尼对健康受试者咖啡因药代动力学的影响评价
本研究在健康受试者中评估利特昔替尼对CYP1A2底物咖啡因药代动力学的影响。单臂固定序列设计下,12名受试者先后单用咖啡因100 mg及在利特昔替尼200 mg每日一次达稳态后合用咖啡因。结果显示咖啡因AUCinf和Cmax分别增加约165%和10%,提示利特昔替尼为CYP1A2中度抑制剂。
要点
- 利特昔替尼200 mg每日一次达稳态可使咖啡因AUCinf增加约165%。
- 咖啡因Cmax仅增加约10%,提示主要影响暴露量而非峰浓度。
- 利特昔替尼为CYP1A2中度抑制剂,合用CYP1A2底物需关注暴露增加。
核心结论
- 利特昔替尼是CYP1A2的中度抑制剂,可增加CYP1A2底物的全身暴露。
研究设计与样本
- 单中心、单臂、开放标签、固定序列研究,纳入12名健康受试者并全部完成。
- 受试者在第1周期第1日单用咖啡因100 mg,第2周期第8日在利特昔替尼200 mg每日一次连续8天达稳态后合用咖啡因100 mg。
- 采用经验证的液相色谱-质谱法测定血样,非房室法估算药代动力学参数。
主要发现
- 与单用咖啡因相比,利特昔替尼达稳态时合用使咖啡因AUCinf和Cmax分别增加约165%和10%。
- 咖啡因AUCinf和Cmax的调整几何均值比(90%CI)分别为265.14%(234.12-300.26%)和109.74%(103.90-15.91%)。
- 利特昔替尼多次给药合用单剂咖啡因在健康受试者中总体安全且耐受良好。
临床怎么用
- 临床合用利特昔替尼与CYP1A2底物时应警惕底物暴露升高,必要时监测疗效与不良反应。
局限性
- 研究仅纳入12名健康受试者,样本量有限。
- 研究为单臂固定序列设计,未设对照臂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This clinical study was conducted to evaluate the impact of ritlecitinib on the pharmacokinetics of caffeine, a cytochrome P450 1A2 (CYP1A2) substrate. METHODS: In this single-centre, single-arm, open-label, fixed-sequence study, healthy participants received a single 100-mg dose of caffeine on 2 separate occasions: on Day 1 of Period 1 as monotherapy and on Day 8 of Period 2 after oral administration of ritlecitinib 200 mg once daily for 8 days. Serial blood samples were collected and analysed using a validated liquid chromatography-mass spectrometry assay. Pharmacokinetic parameters were estimated by using a noncompartmental method. Safety was monitored by physical examination, vital signs, electrocardiograms and laboratory assessments. RESULTS: Twelve participants were enrolled and completed the study. Coadministration of caffeine 100 mg in the presence of steady-state levels of ritlecitinib (200 mg once daily) increased caffeine exposure compared with caffeine given alone. Area under the curve to infinity and maximum concentration of caffeine increased by approximately 165 and 10%, respectively, when coadministered with ritlecitinib. The ratios of the adjusted geometric means (90% confidence interval) for caffeine area under the curve to infinity and maximum concentration were 265.14% (234.12-300.26%) and 109.74% (103.90-15.91%), respectively, when caffeine was coadministered with steady-state ritlecitinib (test) compared with its administration alone (reference). Multiple doses of ritlecitinib when coadministered with a single dose of caffeine were generally safe and well tolerated in healthy participants. CONCLUSION: Ritlecitinib is a moderate inhibitor of CYP1A2 and can increase systemic exposures of CYP1A2 substrates.
引用
- Liu J, Solan R, Wolk R, et al. Evaluation of the effect of ritlecitinib on the pharmacokinetics of caffeine in healthy participants. Br J Clin Pharmacol. 2023. PMID: 36808638. doi:10.1111/bcp.15695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。